Pronovea Pharma Summit 2025: Drug Safety and Risk Management

Pronovea Pharma Summit 2025: Drug Safety and Risk Management is organized by Pronovea and will be held from May 14 - 15, 2025 at Hotel Berlin Potsdamer Platz by Leonardo Hotels, Berlin, Berlin, Germany.

Description:
The Pronovea Pharma Summit 2025 on Drug Safety and Risk Management is designed for industry professionals to address the critical aspects of ensuring drug safety throughout the product lifecycle. This summit brings together leading experts, regulatory bodies, and pharma companies to discuss emerging challenges, best practices, and innovative strategies in managing risks and ensuring patient safety
Through expert-led sessions, case studies, and discussions, attendees will gain insights into global regulatory requirements, risk assessment techniques, pharmacovigilance advancements, and the latest tools for monitoring and mitigating risks.

Key Themes:

• Best practices in pharmacovigilance and risk management.
• Global regulatory standards for drug safety.
• Technological advancements in drug safety monitoring.
• Managing post-market risks and patient safety.

Topic Highlights:

• Addressing inconsistencies in regulatory frameworks across different EU regions and improving global collaboration.
• Exploring the role of AI/ML in predicting adverse events and improving pharmacovigilance processes.
• Enhancing the collection of real-world data to monitor the long-term safety of medications after they reach the market.
• Improving Signal Detection through Big Data and Advanced Analytics: Leveraging large datasets and analytics to enhance the detection and evaluation of safety signals.
• Effective communication of drug safety risks to healthcare professionals, patients, and the public.
• Protecting sensitive data in drug safety systems, particularly as digital tools and cloud technologies become more prevalent.
• Addressing the Rise of Counterfeit Drugs in Global Markets: Strategies for improving drug traceability and combatting counterfeit medicines that pose significant safety risks.
• Ecopharmacovigilance: Reducing environmental impact and enhancing patient safety by integrating eco-pharmacovigilance practices.
• Enhancing pharmacovigilance systems across the EU to ensure real-time monitoring and reporting of adverse drug reactions (ADRs)
• Overcoming the Challenges in Implementing and Optimizing EudraVigilance for Drug Safety in the EU